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A B S T R A C T
A beneficial effect of acetylsalicylic acid (ASA) on vein graft patency has been described, but some patients experience
adverse cardiac events despite appropriate ASA treatment. Study aim was to define ASA resistance using Multiple elec-
trode aggregometry (MEA) preoperatively in group of patients undergoing coronary artery bypass grafting (CABG). Pro-
spective observational trial at University Hospital Center Zagreb enrolled 131 patients scheduled for CABG, and divided
them into 4 groups with respect to preoperative antiplatelet therapy (APT). Group 1 received 100 mg ASA per day, Group
2 100 mg ASA + 75 mg clopidogrel per day, Group 3 75 mg clopidogrel per day, and Group 4 did not receive any APT.
MEA with ASPI test (sensitive to ASA) and ADP test (sensitive to clopidogrel) was performed prior to surgery. In Group
1, patients were characterized as ASA resistant if their ASPI test value exceeded the 75th percentile distribution. Study en-
rolled 131 patients. Significant differences both in the ASPI (p<0.001) and the ADP test (p=0.038) were observed be-
tween patients in different APT groups. In Group (1) ASPI test value of 30 AUC presented 75th percentile of distribution,
thus indicating ASA resistance. Group 2 patients had slightly lower ADP test values, but no significant difference oc-
curred (mean 60.05 vs. 63.32 AUC, p=0.469). In Group 1 and 2, significant correlations between the ADP test and both,
platelet count (r=0.347, p<0.001) and fibrinogen level (r=0.364, p<0.001) were observed. Association between low re-
sponse to ASA and post-CABG major adverse ischemic events risk increase has been described thus indicating need for
ASA resistant patients detection. In patients with preoperative ASPI test exceeding 30 AUC postoperative, ASA dose ad-
justment or clopidogrel addition according to MEA results should be considered.
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Introduction
The outcome of coronary artery bypass graft surgery
(CABG) depends mainly on the patency of the graft ves-
sels. Aortocoronary vein graft disease is comprised of
three distinct but interrelated pathological processes:
thrombosis, intimal hyperplasia and atherosclerosis1. Of
those, early thrombosis is a major cause of vein graft at-
trition during the first month after CABG. Bypass
patency can be improved with antiplatelet therapy (APT)
which is the mainstay of treatment for patients after
CABG. Acetylsalicylic acid (ASA) is the best studied most
used and least toxic of the platelet inhibitors2,3. A benefi-
cial effect of ASA on vein graft patency has been shown
during the first year after CABG4–6. However, some pa-
tients experience adverse cardiac events despite treat-
ment with APT. Some of those events could be caused by
platelet resistance to administered ASA therapy which
inevitably suggests need for antiplatelet drug dose in-
crease, or administration of another antiplatelet agent as
a supplement. Platelet resistance to ASA or clopidogrel
(CLO) administration, as assessed by platelet function
tests, varies widely among patients, and has been repor-
ted to range from 1 to 45% for the 2 drugs7. Recently, a
new point-of-care assay named multiple electrode aggre-
gometry (MEA) using a device called Multiplate analyzer
(Dynabyte, Munich, Germany) has become available at
our department for rapid and standardized assessment
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of platelet function parameters. The aim of this study
was to define and evaluate ASA resistance using MEA
preoperatively in patients following CABG, and to propo-
se the alternative therapeutic approaches in patients
with observed ASA resistance.
Materials and Methods
The study was conducted in a prospective observa-
tional mode at teaching University Hospital Center.
Patient selection
After institutional review board approval and written
informed consent, 131 patients scheduled for elective
CABG were enrolled and divided into 4 groups with re-
spect to their preoperative antiplatelet therapy (APT).
Daily doses of antiplatelet therapy were as follows: group
1 received 100 mg ASA, group 2 received 100 mg ASA +
75 mg clopidogrel, group 3 received 75 mg clopidogrel
and group 4 did not receive any APT prior to surgery pro-
cedure. MEA with ASPI test (sensitive to ASA) and ADP
test (sensitive to clopidogrel) was performed day before
surgery. In Group 1, patients were characterized as ASA
resistant if their ASPI test value exceeded the 75th per-
centile distribution.
Criteria for excluding patients from the group of sub-
jects were: patients with cardiac surgical procedures
other than isolated CABG, patients with inaccurate APT
administration documentation or missing data, an ur-
gent surgery. In our study cohort APT was administered
by the referral cardiologist. In patients admitted to our
department with daily dose of 100 mg ASA, antiplatelet
therapy was continued up to day of surgery. 61/131
(46.56%) of patients received daily dose of 75 mg CLO, ei-
ther alone or in addition to ASA, and CLO was excluded
at our department prior to surgery with individually dif-
ferent time interval from CLO cessation to surgery, from
2 to 8 days, respectively. Time from CLO cessation to sur-
gery varied individually, based on the date of admission
to our department and the date of procedure. Patients re-
ceived APT continuously at least for 10 days prior to ad-
mission to our department. All patients were admitted to
our department at least 1 day before surgery.
Blood sampling
Blood samples for MEA measurements were obtained
day before surgery using venipuncture, and blood was
collected in 4 ml heparin (Lithium Heparin 68 I.U.)
coated BD Vacutainer® plastic tubes. Routine laboratory
tests were performed before surgery. The same person,
not directly involved in patient care, performed MEA
measurements. Blood samples were at rest for 30 minu-
tes after blood withdrawal and MEA was performed sub-
sequently.
Multiple electrode aggregometry (MEA)
Whole blood aggregation was determined using a new
generation impedance aggregometer (Multiplate® ana-
lyzer, Dynabyte Medical, Munich). Detailed description
of method has already been published8. Put briefly, MEA
is based on the principle that blood platelets are non-
-thrombogenic in their resting state, but expose recep-
tors on their surface when they get activated, which al-
low them to attach on vascular injuries and artificial
surfaces. When platelets stick on the Multiplate sensor
wires, they enhance the electrical resistance between
them, which is continuously recorded. Increase in imped-
ance is expressed in arbitrary area under curve (AUC)
units, highlighted as the parameter with the highest di-
agnostic power8,9. The analysis itself needs 3 min for in-
cubation and 6 min for the measurement after stimula-
tion. Platelet aggregation was determined in response to
stimulation with arachidonic acid with a final concentra-
tion of 0.5 mM (ASPI test designed to evaluate ASA ef-
fect) and adenosine diphosphate (ADP) with a final con-
centration of 6.4µM (ADP test designed to evaluate
thienopyridines, such as CLO, effect). In Group 1, pa-
tients were characterized as ASA resistant if their ASPI
test value exceeded the 75th percentile distribution.
Statistics
For statistical analysis we used MedCalc® For Win-
dows software (MedCalc Software, Broekstraat 52, 9030
Mariakerke, Belgium). The Kolmogorov-Smirnov test
was used for evaluating normality of distribution of all
continuous variables. Independent t-test was used for
two study groups’ comparison. Chi square test was used
for data comparison between groups. Value of p=0.05
was considered statistically significant.
Results
Patients
We prospectively ascertained consecutive sample of
131 patients scheduled for elective CABG. All patients
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TABLE 1.
COMPARISON OF ASPI TEST (AUC) AND ADP TEST (AUC)
VALUES WITHIN DIFFERENT ANTIPLATELET THERAPY
GROUPS REVEALS SIGNIFICANT DIFFERENCES BOTH IN
ASPI (P<0.001) AND ADP (P=0.038) TEST VALUES
N Mean
Std.
Deviation
ASPI test
(AUC)
Group 1* 65 25.14 18.773
Group 2† 56 22.48 14.315
Group 3‡ 5 79.00 15.700
Group 4§ 5 103.60 27.736
ADP test
(AUC)
Group 1* 65 63.32 24.101
Group 2† 56 60.05 25.344
Group 3‡ 5 68.40 35.133
Group 4§ 5 93.80 19.162
* monotherapy acetylsalicylic acid group, †dual antiplatelet the-
rapy group (acetylsalicylic acid and clopidogrel), ‡ monotherapy
clopidogrel group, § without antiplatelet therapy group.
from the sample were discharged from hospital. Cohort
group was divided in four subgroups regarding antipla-
telet therapy management. Both ASPI and ADP test
were compared between groups (Table 1). We found sig-
nificant difference between groups concerning both
ASPI (p<0.001) and ADP (p=0.0385) test as shown in
Figure 1 and Figure 2, respectively. In order to assess
platelet response to ASA therapy only patients in Group
1 and Group 2 were included in further analysis. No dif-
ference occurred between Group 1 and Group 2 concern-
ing demographic, laboratory and operative data (Table
2). Group 2 patients had slightly lower ADP test values,
but no significant difference occurred (mean 60.05 vs.
63.32 AUC, p=0.469). In addition to, Group 2 patients
had lower ASPI test values (mean 22.48 vs. 25.14 AUC,
p=0.38), but the difference did not reach statistical sig-
nificance.
In order to avoid greater inhibitory effect of dual
antiplatelet therapy on platelet aggregation comparing
to either agent alone, we decided to define ASA resistan-
ce in group of patients receiving daily dose of 100 mg
ASA only. In Group 1, ASPI test value of 30 AUC pre-
sented 75th percentile of distribution, thus indicating
cut-off value for ASA resistance definition.
In Group 1 and Group 2, demographic, laboratory and
operative data were correlated to both ASPI and ADP
test values (Table 3). Significant correlations between
the ADP and both, platelet count (r=0.347, p<0.001)
and fibrinogen level (r=0.364, p<0.001) were described
taking into consideration both groups together. ASPI test
values did not correlate to platelet count and fibrinogen
(p=ns).
Given the presence on ASA resistance, demographic,
laboratory and operative data among the groups receiv-
ing ASA therapy were compared. Only difference occur-
red among red blood cells count. ASA resistant patients
had higher values (4.77 vs. 4.52, p=0.017). Although sta-
tistically significant, we found it of no clinical relevance.
In Group 2 with dual antiplatelet therapy administra-
tion, ADP test value was correlated to number of days af-
ter CLO withdrawal. There was no significant correla-
tion (r=0.01, p=0.99).
Discussion and Conclusion
This study defined ASA resistance using MEA in pa-
tients undergoing CABG. To our knowledge this is first
study with definition of ASA resistance using MEA in
group of patients undergoing CABG. In our opinion, the
lack of objective quantification of the antiplatelet effect
of both ASA and CLO constitutes a major drawback of
antiplatelet therapy management in coronary artery dis-
ease patients. The incidence of ASA resistance varies
widely in the literature1 and independently raises the in-
cidence of adverse cardiovascular events and venous
graft occlusions1. Therefore it would be critical to detect
ASA resistance preoperatively and adjust for this vari-
able in postoperative phase.
Our study presumably identified a group of patients
with preoperative ASA resistance. No uniform guidelines
exist for the postoperative prevention of thrombotic com-
plications after CABG10. It is widely accepted that plate-
lets play a pivotal role in the development of thrombosis
11,12. Early graft failure is hypothesized to be related to
thrombus development, of which ASA resistance may be
an important component13.
Several laboratory assays are commonly used to assess
response to APT. The fact that aggregation in MEA takes
place on surfaces is a major difference compared to other
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Fig. 1. Differences in ASPI test values (AUC) between groups
with respect to preoperative antiplatelet therapy management.
(Group 1: 100 mg acetylsalicylic acid daily dose, Group 2: 100
mg acetylsalicylic acid + 75 mg clopidogrel daily dose, Group 3:
75 mg clopidogrel daily dose, Group 4: no antiplatelet therapy
administered).
Fig. 2. Differences in ADP test values (AUC) between groups with
respect to preoperative antiplatelet therapy management. (Group
1: 100 mg acetylsalicylic acid daily dose, Group 2: 100 mg ace-
tylsalicylic acid + 75 mg clopidogrel daily dose, Group 3: 75 mg
clopidogrel daily dose, Group 4: no antiplatelet therapy adminis-
tered).
methods such as Born aggregometry and single platelet
counting. MEA uses anticoagulated whole blood for anal-
ysis. Whole blood is the physiological environment where
platelet function takes place in vivo, and the use of whole
blood for in vitro testing eliminates the need for time-
-consuming centrifugation steps required for Born aggre-
gation measurements. The ideal anticoagulant for accu-
rate platelet aggregometry remains controversial. Citra-
te is still now used as the anticoagulant of choice for
platelet testing. At our department only citrate and hepa-
rin are available as blood sample anticoagulants. Hepa-
rin may be used as an anticoagulant for platelet aggrega-
tion studies14,15 although early literature refers heparin
to affect aggregation results16. Therefore, different refer-
ence interval of test values should be considered. We ob-
tained blood samples by performing anticoagulation with
heparin. Our definition is in concordance to literature
sources published by our institutional colleagues with
the same setting used in cohort of 110 patients with sta-
ble coronary artery disease receiving daily dose of 100 mg
ASA17. Similar results were also described, although with
different anticoagulant used for blood sampling for
MEA18,19. Truss et al.14 has compared aggregation data
obtained performing MEA using either citrate or heparin
as an anticoagulant. MEA responses to arachidonic acid,
ADP and collagen, obtained with heparin as anticoagu-
lant resulted in lower values than data obtained with cit-
rated blood. Taking into consideration the fact we regu-
larly use unfractioned heparin as an anticoagulant for
MEA we made our own definition of ASA resistance
which is applicable for use in the setting of heparin as an
anticoagulant for blood sample.
Currently, there is no established therapeutic approach
for managing ASA resistance that has been shown in
large trials to have clinical benefit. Our data presumably
identified a subgroup of patients with ASA resistance
who may be at increased risk for developing thrombo-
embolic complications. In this subgroup of patients hi-
gher doses of ASA should be considered in postoperative
phase. At our Department of Cardiac Surgery 300 mg
ASA is routinely administered in postoperative phase
starting on first postoperative day. If ASA resistance oc-
curs in postoperative phase despite 300 mg ASA adminis-
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TABLE 2.
BASIC DEMOGRAPHIC, LABORATORY AND OPERATIVE DATA
Group N Mean SD P
EuroScore (%)
Group 1* 65 3.57 3.59 0.334
Group 2† 56 3.00 2.69
Body mass index (kg/m2)
Group 1 65 28.20 4.01 0.843
Group 2 56 28.33 3.48
Body surface area (m2)
Group 1 65 1.97 0.21 0.817
Group 2 56 1.98 0.19
Age (years)
Group 1 65 64.65 8.01 0.438
Group 2 56 63.52 7.87
Red blood cell count (cells/mcL)
Group 1 65 4.54 0.53 0.312
Group 2 56 4.63 0.44
Hemoglobin (g/L)
Group 1 65 135.82 16.41 0.553
Group 2 56 137.52 14.83
Hematocrit (x100%)
Group 1 65 0.40 0.05 0.363
Group 2 56 0.41 0.04
Platelet count (x109/L)
Group 1 65 211.48 61.18 0.169
Group 2 56 227.96 69.76
Fibrinogen (g/L)
Group 1 65 3.80 0.89 0.387
Group 2 56 3.95 1.08
ASPI (AUC)
Group 1 65 25.14 18.77 0.389
Group 2 56 22.48 14.31
ADP (AUC)
Group 1 65 63.32 24.10 0.469
Group 2 56 60.05 25.34
Cross clamp time (min)
Group 1 65 63.54 23.01 0.381
Group 2 56 59.93 21.96
Cardiopulmonary bypass time (min)
Group 1 65 91.42 27.06 0.130
Group 2 56 83.95 26.61
* monotherapy acetylsalicylic acid group, †dual antiplatelet therapy group (acetylsalicylic acid and clopidogrel)
tration, further increase in ASA dosage would not be
prudent in terms of worsening endothelial – mediated ar-
terial dilatation20. These patients could benefit from a
more aggressive antithrombotic treatment regimen such
as dual antiplatelet therapy with CLO addition to ASA
therapy. ASA resistance is a transient phenomenon pres-
ent in the majority of the patients undergoing coronary
artery bypass grafting21. Without quantitative preopera-
tive platelet function assessment, and subsequent ASA
resistant patients detection it is quite hard to distinguish
permanent from transient platelet hyperactivity follow-
ing CABG. We propose alternative APT management in
patients with ASA resistance. CLO therapy could affect
the graft patency in patients with ASA resistance. Preop-
eratively detected ASA resistant patients are more likely
to be ASA resistant in postoperative period. However,
some patients with adequate platelet inhibition prior to
surgery can develop transient ASA resistance in the post-
operative period. Assessment of platelet function prior to
CABG with ASA resistant patient detection may advise
to ASA dose increase or switch to dual antiplatelet thera-
py in postoperative phase. Postoperative assessment of
platelet function can detect platelet function changes
and propose APT adjustment according to both ASPI and
ADP test values. However, this therapeutically approach
needs randomized control trial with large study group to
evaluate the benefit of such treatment. The benefit of
such a treatment regimen has been investigated in CAS-
CADE trial 22. The authors investigated on the impact of
dual antiplatelet therapy on venous graft disease in
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TABLE 3.
CORRELATION BETWEEN DEMOGRAPHIC, LABORATORY AND OPERATIVE DATA TO BOTH ASPI AND ADP TEST VALUES
IN GROUP 1 AND GROUP 2.
Group 1* Group 2†
ASPI test (AUC) ADP test (AUC) ASPI test (AUC) ADP test (AUC)
Body mass index
(kg/m2)
Pearson Correlation 0.001 –0.082 –0.130 –0.052
p 0.996 0.516 0.339 0.702
N 65 65 56 56
Body surface area
(m2)
Pearson Correlation 0.033 –0.234 –0.165 –0.101
p 0.794 0.061 0.223 0.458
N 65 65 56 56
Age
(years)
Pearson Correlation 0.063 –0.082 –0.091 0.126
p 0.620 0.517 0.503 0.356
N 65 65 56 56
Red blood cell
count (cells/mcL)
Pearson Correlation 0.273 0.059 0.118 –0.126
p 0.029 0.645 0.387 0.354
N 65 65 56 56
Hemoglobin
(g/L)
Pearson Correlation 0.198 –0.005 0.087 –0.240
p 0.113 0.970 0.523 0.074
N 65 65 56 56
Hematocrit
(x100%)
Pearson Correlation 0.223 –0.011 0.100 –0.198
p 0.075 0.928 0.463 0.144
N 65 65 56 56
Platelet count
(x109/L)
Pearson Correlation 0.150 0.429 0.154 0.292
p 0.233 <0.001 0.257 0.029
N 65 65 56 56
Fibrinogen
(g/L)
Pearson Correlation 0.090 0.424 0.078 0.326
p 0.482 0.001 0.567 0.014
N 65 65 56 56
Cross clamp
time (min)
Pearson Correlation –0.080 –0.113 –0.255 0.194
p 0.526 0.370 0.057 0.152
N 65 65 56 56
Cardiopulmonary
bypass time (min)
Pearson Correlation –0.121 –0.144 –0.280 0.194
p 0.338 0.252 0.037 0.152
N 65 65 56 56
* monotherapy acetylsalicylic acid group, †dual antiplatelet therapy group (acetylsalicylic acid and clopidogrel)
CABG patients. The primary outcome was saphenous
vein graft intimal hyperplasia, determined by intravas-
cular ultrasound. Secondary outcomes were graft paten-
cy, major adverse cardiovascular events, and major bleed-
ing. No significant difference occurred regarding both
the primary and secondary outcomes between ASA-CLO
and ASA-placebo postoperative APT regimen group. The
lack of objective quantification of the antiplatelet effect
of both ASA and CLO constitutes a major drawback of
the study23. Nevertheless, since ASA resistance raises
the incidence of adverse cardiovascular events and ve-
nous graft occlusions, it would seem critical to adjust for
this variable1. This problem was further amplified by ig-
noring the variability to CLO response. Therefore, ran-
domization of patients with MEA assessed inappropriate
response to ASA on CLO or placebo addition could reveal
different results. Further, MEA evaluation of response to
CLO in group receiving dual antiplatelet therapy could
be useful. Another alternative therapeutic approach to
ASA resistant patients is mono antiplatelet therapy with
CLO. The Aspirin Non-Responsiveness and Clopidogrel
End point Trial (ASCET) is currently evaluating whe-
ther switching to CLO will be superior to continuing ASA
therapy in improving clinical outcomes in ASA low res-
ponders24.
Using MEA to guide APT may allow individual tailor-
ing therapy after MEA assessment in postoperative pha-
se. Individual tailored therapeutic approach could signif-
icantly improve clinical outcomes. Awidi et al found that
the combination of ASA and CLO had greater inhibitory
effects on platelet function than either agent alone3. In
our study, although slightly lower, ASPI test values did
not differ significantly between group receiving ASA
monotherapy and dual antiplatelet therapy (p=ns). Pro-
spective, outcome evaluating randomized trials, with pla-
telet function assessment are needed to clarify the bene-
fits of dual antiplatelet therapy. Bochsen et al suggested
that CABG patients are prone to platelet hyperactivity at
fourth postoperative day25. In addition to Kempfert et al
reported 28.8% patients with ASA resistance before
CABG. Postoperatively almost half of patients (49%) de-
veloped ASA resistance21. Comprehensive platelet func-
tion assessment both pre- and postoperatively can distin-
guish patients who need temporary or permanent increase
of ASA dose or CLO addition. Routine platelet function
assessment in patients on APT can provide optimal APT
safety profile concerning both ischemic and bleeding
events. Standard definition to assess antiplatelet drug
response has not been fully established and differences
in assays, agonist concentrations and cut-off values have
contributed to the existing variability7. Antiplatelet re-
sponse to ASA, as assessed by platelet function tests, var-
ies widely among the patients, and that could possibly ex-
plain early graft occlusion within the first month after
surgery despite appropriate ASA treatment6. Therefore,
a more aggressive antithrombotic treatment might be
warranted for patients with ASA resistance in postopera-
tive period.
Limitations of study
The study was conducted as prospective observatio-
nal, and we did not analyze the outcome with respect to
MEA results and the scope of this study was not to iden-
tify the event rate of thromboembolic complication with
regards to ASA resistance. The purpose of study was to
define ASA resistance in bedside laboratory setting in
group of patients undergoing CABG. Although we as-
sessed ADP test preoperatively we did not assessed CLO
resistance in group of patients with recent CLO adminis-
tration. The reason is in the fact that measurements
were performed the day before surgery, and CLO was ex-
cluded from therapy in different time intervals from
measurements, so technically it would be impossible to
mark someone to be CLO resistant with different time
intervals from CLO withdrawal to time of platelet func-
tion assessment. As we already described, there was no
correlation of ADP test and number of days after CLO
withdrawal. The degree of platelet inhibition after CLO
treatment varies from patient to patient, and 4 to 30% of
patients treated with CLO do not have adequate antipla-
telet response26. In addition to, the great variability in
ADP test values could be result of different inherent
platelet ADP receptor activity with different proportion
of newborn platelets ADP receptors activity after CLO
withdrawal. However, in absence of MEA in routine clini-
cal practice, strong correlations of ADP test (sensitive to
CLO effect) and both platelet count (p<0.001) and
fibrinogen level (p<0.001) may advise administration of
CLO in patients with high fibrinogen and platelet count
values.
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DEFINICIJA REZISTENCIJE NA ACETILSALICILNU KISELINU UPOTREBOM IMPEDANCIJSKE
AGREGOMETRIJE KOD BOLESNIKA KOJI SE PODVRGAVAJU OPERACIJI KORONARNOG
PREMO[TENJA
S A @ E T A K
Povoljan u~inak acetilsalicilne kiseline na prohodnost venskih graftova ve} je opisana, ali odre|eni broj bolesnika
poslijeoperacijski do`ivi nepovoljna ishemijska zbivanja unato~ adekvatnom lije~enju acetilsalicilnom kiselinom. Cilj
studije je prijeoperacijski definirati rezistenciju na acetilsalicilnu kiselinu upotrebom impedancijske agregometrije (MEA)
u skupini bolesnika koji se podvrgavaju operaciji koronarnog premo{tenja (CABG). Prospektivna opservacijska studija
u Klini~kom bolni~kom centru Zagreb uklju~ila je 131 bolesnika kod kojih je planiran CABG. Bolesnici su podijeljeni u
4 skupine obzirom na prijeoperacijski ordiniranu antiagregacijsku terapiju. Skupina 1 je primala acetilsalicilnu kise-
linu 100 mg/dnevno, skupina 2 100 mg acetilsalicilne kiseline te 75 mg klopidogrel dnevno, skupina 3 je primala klopi-
dogrel 75 mg dnevno dok skupina 4 nije primala antiagregacijsku terapiju prije operacije. MEA s ASPI testom (koji je
senzitivan na u~inak acetilsalicilne kiseline) i ADP testom (senzitivan na u~inak klopidogrela) je izvedena prije opera-
cije. U skupini 1, bolesnici kojima je vrijednost ASPI testa iznosila vise od 75. percentile distribucije vrijednosti ASPI
testa su okarakterizirani kao rezistentni na acetilsalicilnu kiselinu. Zna~ajne razlike u vrijednostima ASPI (p<0.001) i
ADP testa (p=0.038)uo~ene su izme|u skupina bolesnika definiranih prema re`imu prijeoperacijskog antiagregacijskog
lije~enja. U skupini 1, vrijednost ASPI testa od 30 AUC (engl. area under curve) je predstavljala vrijednost 75-te percen-
tile, ozna~avaju}i grani~nu vrijednos za definiciju rezistencije na acetilsalicilnu kiselinu.U skupini 2 (izlo`eni klopi-
dogrelu) izmjerene su ni`e vrijednosti ADP testa, me|utim bez statisti~ki zna~ajne razlike (srednja vrijednost 60.05 vs.
63.32 AUC, p=0.469). U skupini 1 i 2,uo~ene su zna~ajne korelacije izme|u vrijednosti ADP testa i broja trombocita
(r=0.347, p<0.001) te razine fibrinogena (r=0.364, p<0.001).Povezanost izme|u izostanka odgovora na acetilsalicilnu
kiselinu i pove}anog rizika za ne`eljena poslijeoperacijska ishemijska zbivanja je ve} opisana {to nagla{ava potrebu za
brzim i lakoizvedivim definiranjem bolesnika s rezistencijom na acetilsalicilnu kiselinu. Kod bolesnika s prijeopera-
cijskim vrijednostima ASPI testa ve}im od 30 AUC, trebalo bi razmotriti prilagodbu doze acetilsalicilne kiseline ili
dodavanje klopidogrela (tzv. dvojna antiagregacijska terapija) na osnovi MEA monitoriranja.
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